Article citationsMore>>

Fang, F., Wang, E., Yang, H., Zhao, T., Wang, Q., Zhang, Z., et al. (2025) Reprogramming Mitochondrial Metabolism and Epigenetics of Macrophages via miR-10a Liposomes for Atherosclerosis Therapy. Nature Communications, 16, Article No. 9117. https://doi.org/10.1038/s41467-025-64201-8

has been cited by the following article:

• TITLE: Application of Drug Delivery Systems in the Treatment of Atherosclerosis

  AUTHORS: Xiaoyu Liang, Xiaoqiong Cui, Zhiyuan Li, Junyi Wang, Xiaomin Hu, Jing Yang, Wenqing Gao

  KEYWORDS: Atherosclerosis, Drug Delivery Systems, Liposomes, Biomimetic Delivery, Targeted Therapy, Inflammation, Oxidative Stress

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.14 No.5, May 29, 2026

  ABSTRACT: Atherosclerosis (AS) is a progressive chronic inflammatory disease and the primary cause of global cardiovascular mortality, characterized by lipid deposition, endothelial dysfunction, foam cell formation, and plaque development. Conventional pharmacological interventions suffer from non-specific distribution, low bioavailability, and severe side effects, limiting their clinical efficacy. Rationally designed drug delivery systems (DDSs), including conventional liposomes, polymeric nanoparticles, micelles, dendrimers, hydrogels, and novel biomimetic, nanomotor, and mitochondria-targeted platforms, have emerged as promising strategies. These DDSs enable precise targeting to atherosclerotic plaques, controlled drug release, prolonged circulation time, and enhanced therapeutic efficacy while reducing adverse effects. This review systematically summarizes the classification, design principles, and applications of DDSs in AS treatment, highlighting their potential for optimizing AS diagnosis and therapy.